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Current diagnostic strategies for undifferentiated tumours of the nasal cavities and paranasal
sinuses
Several malignant tumours occurring in the sinonasal
tract may present with an undifferentiated morphol-
ogy. Overall, these lesions pose significant diagnostic
difficulties for the surgical pathologist, especially in
limited biopsy material, but their correct classification
is becoming increasingly important for an appropriate
treatment strategy. This review deals with the criteria
for differential diagnosis of these neoplasms, with
emphasis on recent advances in immunohistochemis-
try and molecular biology, as well as with previous
progress in electron microscopy. Through careful
microscopic examination of haematoxylin and eosin-
stained sections, in the light of clinical information and
imaging data, a list of differential diagnoses can be
made and an appropriate panel of antibodies can be
chosen to further categorize the tumour. An initial
panel including cytokeratins, synaptophysin, S100
protein, desmin and CD45 may allow the classification
of most lesions or may help to narrow the list of
differential diagnoses. Further refinement can be obtai-
ned through second-line markers, including in-situ
hybridization for Epstein–Barr virus, other neuroendo-
crine markers, melanocytic markers, myogenin, CD99,
other lymphocyte markers, and CD138 and light
chains. Finally, molecular analysis can further assist
in the recognition of specific entities such as
nuclear protein in testis midline carcinoma, Ewing’s
sarcoma ⁄ peripheral neuroectodermal tumour, alveolar
rhadbomyosarcoma, and poorly differentiated synovial
sarcoma.
Keywords: diagnosis, electron microscopy, immunohistochemistry, molecular biology, nasal cavity, paranasal
sinuses, undifferentiated tumours
Abbreviations: ACC, adenoid cystic carcinoma; BSCC, basaloid squamous cell carcinoma; CCC, cylindrical cell
carcinoma; CK, cytokeratin; EBV, Epstein–Barr virus; EMA, epithelial membrane antigen; GFAP, glial fibrillary acidic
protein; HPV, human papilloma virus; NK, natural killer; NMC, nuclear protein in testis midline carcinoma; NPTUC,
nasopharyngeal-type undifferentiated carcinoma; NSE, neuron-specific enolase; NUT, nuclear protein in testis;
ON, olfactory neuroblastoma; PNET, peripheral neuroectodermal tumour; RMS, rhabdomyosarcoma; SCC, squa-
mous cell carcinoma; SCNEC, small-cell neuroendocrine carcinoma; SNUC, sinonasal undifferentiated carcinoma
Introduction
Malignant tumours of the nasal cavities and paranasal
sinuses represent about 3.6% of all malignancies
arising in the head and neck area.1 Data from cancer
registries indicate that approximately two-thirds of
primary sinonasal malignancies are of epithelial origin,
although there are significant differences in the distri-
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bution of histological subtypes in different countries,
possibly related to variable exposure to risk factors.2
Several of the malignant tumours occurring primar-
ily in the sinonasal tract may present with an undif-
ferentiated or poorly differentiated morphology, being
composed of small to medium and large, round or
polygonal atypical cells.3–5 Overall, they pose signifi-
cant diagnostic difficulties for the surgical pathologist,
especially in limited biopsy material, but their correct
classification by means of histology, immunohisto-
chemistry or molecular biology is becoming increas-
ingly important for choosing an appropriate treatment
strategy.6,7 In addition, poorly differentiated neoplasms
may involve the sinonasal region through spread from
local sites (oral cavity, nasopharynx, or skull base)
or by metastasis from distant sites. Although these
occurrences are exceedingly rare, the clinical history
and the results of imaging studies should be available
for an accurate differential diagnosis.
In recent years, the spectrum of primary sinonasal
undifferentiated neoplasms has enlarged, because new
entities specific to this region or initially described in
other locations have been recognized. In addition,
several new immunohistochemical and molecular
markers have been tested on these neoplasms, and
they facilitate, in combination with light and ultra-
structural morphology, their correct classification.
To follow a practical diagnostic approach, sinonasal
undifferentiated neoplasms can be broadly divided into
epithelial and non-epithelial neoplasms (Table 1).
The first group primarily includes sinonasal undiffer-
entiated carcinoma (SNUC), sinonasal nasopharyngeal-
type undifferentiated carcinoma (NPTUC), small-cell
neuroendocrine carcinoma (SCNEC), and nuclear
protein in testis (NUT) midline carcinoma (NMC), but
several other sinonasal carcinomas, such as squamous
cell carcinoma (SCC) and its variants, as well as
glandular neoplasms such as adenoid cystic carcinoma
(ACC), may have a poorly differentiated histological
aspect requiring differential diagnosis.
The group of non-epithelial malignancies includes:
(i) neuroectodermal tumours (tumours with neuro-
ectodermal differentiation) – olfactory neuroblastoma
(ON), Ewing’s sarcoma ⁄ peripheral neuroectodermal
tumour (PNET), and malignant melanoma; (ii) sinona-
sal malignant haematological neoplasms – lymphomas,
plasmacytoma, granulocytic sarcoma, and histiocytic
sarcoma; and (iii) sarcomas – rhabdomyosarcoma
(RMS), mesenchymal chondrosarcoma, poorly differ-
entiated synovial sarcoma, and desmoplastic small
round cell tumour.
The purpose of this review is to discuss the criteria
for differential diagnosis of these neoplasms, with
emphasis on recent advances in immunohistochemis-
try and molecular diagnostics, as well as previous
progress in electron microscopy.
Epithelial neoplasms
snuc
SNUC is a highly aggressive anaplastic epithelial
neoplasm of the nasal cavity and paranasal sinuses
that occurs in both sexes over a wide age range, with a
median in the sixth decade of life.8 It frequently
originates from the ethmoid region as a large fungating
mass with invasion of adjacent sinonasal structures, as
well as the orbit, skull base, and brain. Microscopically,
it is composed of sheets, nests or ribbons of small to
medium-sized cells, lacking evidence of squamous or
glandular differentiation.9–15 These cells are polygonal
in shape, showing round to ovoid, hyperchromatic or
vesicular nuclei, with either inconspicuous or slightly
Table 1. Potential range of sinonasal tumours that may
present with an ‘undifferentiated’ morphology
Epithelial
Sinonasal undifferentiated carcinoma
Nasopharyngeal-type undifferentiated carcinoma
(lymphoepithelioma)
NUT midline carcinoma
Small-cell neuroendocrine carcinoma
Squamous cell carcinoma and variants
Non-epithelial
Neuroectodermal tumours
Melanoma
Olfactory neuroblastoma
Ewing’s sarcoma ⁄ PNET
Haematolymphoid tumours
Non-Hodgkin lymphomas
Extramedullary plasmacytoma
Extramedullary myeloid sarcoma
Mesenchymal tumours
Rhabdomyosarcoma
Mesenchymal chondrosarcoma
Synovial sarcoma
Desmoplastic small round cell tumour
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prominent nucleoli, and moderate amounts of eosino-
philic cytoplasm (Figure 1). There are numerous
mitotic figures, and necrosis and vascular invasion
are frequently present. Ultrastructural studies have
demonstrated rare dense core granules, indicative of
neuroendocrine differentiation, and poorly formed
desmosomes. Immunohistochemically, SNUC is positive
for epithelial markers, such as simple epithelia cyto-
keratins (CKs)16 and epithelial membrane antigen
(EMA). Variable reactivity can be seen with neuron-
specific enolase (NSE), chromogranin, and synaptophy-
sin. SNUC is typically negative for Epstein–Barr virus
(EBV).14,15
The main differential diagnosis of SNUC is with high-
grade ON, and this is clinically relevant, because SNUC
has a much worse prognosis than ON. The two entities
share clinical, light microscopic and ultrastructural
features, but SNUC is consistently CK-positive and lacks
the typical S100-positive cells around tumour nests, as
seen in ON. Conversely, ON is only occasionally and
focally positive for CKs, and it is consistently positive for
neural markers.
In addition, SNUC needs to be distinguished from
other primary sinonasal carcinomas, such as SCNEC,
solid ACC, cylindrical cell carcinoma (CCC), and
NPTUC, and from malignant melanoma.
primary sinonasal nptuc
(lymphoepithelioma)
NPTUC may occur in the sinonasal tract, both as a
primary lesion,15 and by extension from a primary
nasopharyngeal tumour. Owing to the undifferentiated
appearance of neoplastic cells in NPTUC, examples
of these lesions may be lumped together with SNUC if
one is unaware of their occurrence.14,15 Indeed, SNUC
does not arise in the nasopharynx, but larger tumours
may extend to involve this region. The distinction of
these entities is important, because NPTUC has a better
prognosis and is more responsive to radiation therapy
than SNUC. The differential diagnosis between these
tumours can generally be made on purely histological
grounds, because, in NPTUC, neoplastic cells lack
distinct borders, show a syncytial growth pattern,
and have markedly vesicular nuclei with prominent
nucleoli, and a lymphoplasmacytic cell infiltrate is seen
in most cases (Figure 2). Immunohistochemistry and
in-situ hybridization are of great help in difficult cases.
Expression of CK5 ⁄ 6 and CK13 supports the diagnosis
of NPTUC, whereas these markers are notably absent in
SNUC.16 Immunohistochemical staining for p63 can
also assist in this differential diagnosis, as NPTUC
shows strong and diffuse p63 expression, whereas this
marker is only focally positive in cases of SNUC.17,18
Finally, at variance with lymphoepithelioma-like undif-
ferentiated carcinoma of the head and neck at ‘ectopic’
sites, which is EBV-negative,19,20 sinonasal NPTUC is
constantly positive, making this a useful test for the
differential diagnosis with SNUC, which is nega-
tive.14,15 Quite recently, lymphoepithelioma-like
undifferentiated carcinoma of the oropharynx and
nasopharynx has been shown to be p16-positive and
Figure 1. Sinonasal undifferentiated carcinoma. The tumour is
composed of sheets and ribbons of undifferentiated round cells, with a
high nuclear ⁄ cytoplasmic ratio. Tumour cells are positive for
cytokeratin 8 (upper right) and negative for cytokeratin 5 ⁄ 6 (lower
right).
Figure 2. Nasopharyngeal-type undifferentiated carcinoma. The
tumour has a syncitial growth pattern, with cells showing indistinct
margins and round vesicular nuclei with prominent nucleoli.
Numerous lymphocytes are associated with the neoplastic prolifera-
tion. Tumour cells are positive for cytokeratin 5 ⁄ 6 (upper right)
and for Epstein–Barr virus (EBER-1, lower right).
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human papilloma virus (HPV)16-positive by in-situ
hybridization.21,22
scnec
SCNEC occurs at various sites in the upper aerodigestive
tract, but it quite rarely involves the sinonasal region.
It is a highly aggressive tumour that occurs more often
in adults.6,23 Cases following radiation therapy for other
head and neck malignancies have been reported in both
adult and paediatric patients.24–26
Sinonasal SCNEC is histologically indistinguishable
from its pulmonary counterpart, being composed of
sheets or nests of closely packed cells with inconspic-
uous cytoplasm and round, oval or spindle nuclei with
dense chromatin and absent nucleoli (Figure 3). How-
ever, there are lesions that do not fit this definition;
these consist of larger cells with round nuclei contain-
ing finely dispersed chromatin with conspicuous or
small nucleoli, but still showing immunohistochemical
and ⁄ or ultrastructural evidence of diffuse neuro-
endocrine differentiation. These tumours have also
been referred to as ‘non-small-cell neuroendocrine
carcinoma’.27
Immunohistochemically, SCNEC is positive for CKs
(AE1 ⁄ AE3 and CAM5.2) and neuroendocrine markers
such as NSE, synaptophysin, and chromogranin,
although with variable frequency.4,24 Like SCNEC of
other sites, sinonasal tumours express CD57.4,28 These
features allow the distinction from SNUC, malignant
melanoma, ON, lymphoma, Ewing’s sarcoma ⁄ PNET,
and RMS.
nmc
NMC is a rare, highly aggressive carcinoma that is
defined by a translocation involving the NUT gene on
chromosome 15q14 and, in most cases, the BRD4 gene
on chromosome 19p13.1.29 The translocation results
in a BRD4–NUT fusion gene, which encodes for a
protein that is thought to be involved in a block of
epithelial differentiation and squamous maturation.30
Initially, cases were reported in young patients affected
by intrathoracic carcinomas, but it is now well estab-
lished that these tumours may occur in adults and
involve other anatomical sites of the midline axis. The
exact frequency of NMC is currently unknown, but in a
recent study it represented 18% of poorly differentiated
carcinomas of the upper aerodigestive tract.31 So far,
fewer than 10 cases have been described in the nasal
cavity and paranasal sinuses.29,31,32 These tumours
affected young adults of both sexes and showed an
aggressive clinical behaviour. However, there is increas-
ing evidence that the distinction of NMC from other
sinonasal carcinomas is of clinical relevance, in view of
the favourable response to certain treatment regimens,
including chemotherapy according to Ewing’s sarcoma
protocols or docetaxel and radiotherapy.33,34
Histologically, NMC is composed of undifferentiated
basaloid cells with focal, often abrupt, squamous
differentiation (Figure 4). In some instances, squamous
differentiation may be more pronounced.35 The diag-
nosis of NMC requires the demonstration of the NUT
translocation, which can be obtained by karyotyping,
reverse transcription polymerase chain reaction, and
fluorescence in-situ hybridization. Recently, a mono-
clonal antibody to NUT for use in immunohistochem-
istry has been developed, and showed a sensitivity of
87%, a specificity of 100%, a negative predictive value
of 99% and a positive predictive value of 100% when
tested in a large panel of carcinoma tissues.36 The use
of this antibody may help to separate NMC from other
poorly differentiated sinonasal carcinomas, thus
contributing to their clinicopathological characteriza-
tion. Other immunohistochemical markers that were
found to be consistently positive in NMC are CKs and
p63, whereas no immunoreactivity has been observed
with muscle, neuroendocrine and melanocytic mark-
ers.37 The presence of HPV and EBV infection has never
been identified, by either immunohistochemistry,
in-situ hybridization, or polymerase chain reaction.37
scc and variants
SCC is the most frequent epithelial neoplasm of the
sinonasal tract, and occasionally can have a poorly
Figure 3. Sinonasal small-cell neuroendocrine carcinoma. The
tumour has a nested architecture, and is composed of round cells
with scant cytoplasm and round to oval nuclei with stippled
chromatin. Dot-like paranuclear immunoreactivity for cytokeratins
(upper right) and diffuse positivity for neuron-specific enolase (NSE)
(lower right) is observed.
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differentiated appearance, with little or no evidence of
keratinization in a small biopsy specimen, necessitating
differential diagnosis from other carcinomas. Other
variants of SCC occurring in the nasal cavities and
paranasal sinuses that may have an ‘undifferentiated’
histological appearance are CCC and basaloid SCC
(BSCC). Microscopically, CCC is composed of papillary
fronds, thick ribbons and stratified masses of cells that
quite often give rise to invaginations of the surface
epithelium. The tumour cells are commonly cylindrical,
and have a tendency to form palisade arrangements
perpendicular to the underlying basement membrane.
In poorly differentiated variants, neoplastic cells lose
this ordered architecture, and the lesion is formed by
ribbons and nests of large polygonal cells. Recent
molecular and immunophenotypic studies support the
concept that CCC is a distinct entity characterized by a
high prevalence of high-risk HPV DNA, overexpression
of p16 protein, a high Ki67 labelling index, and
negative or low p53 reactivity, whereas conventional
sinonasal keratinizing SCC is a tumour more frequently
related to cigarette smoking, with a high frequency of
p53 anomalies.38,39
BSCC is an aggressive SCC variant that rarely
involves the sinonasal tract.40 Histologically, it is
characterized by lobules of highly atypical basaloid
cells, often displaying peripheral palisading. Squamous
differentiation is present, although it may not be readily
apparent in small biopsy specimens, making the sepa-
ration from other carcinomas difficult. Recently, it
has been shown that a subset of BSCC of the upper
aerodigestive tract is associated with HPV.41,42 These
tumours affect younger patients, have a more favour-
able outcome, and are strongly associated with immu-
nohistochemical p16 positivity and p53 negativity.41,42
All SCC variants are CK-positive, allowing the
distinction from non-epithelial neoplasms, and express
CK subtypes (CK5 ⁄ 6, CK13, and CK19) that are not
expressed by SNUC.16 Expression of neuroendocrine
markers has been reported in BSCC,28 but distinction
from SCNEC can be based on immunostaining for
CK34bE12, which is positive in BSCC and negative
in SCNEC.28 P63 immunostaining may be a useful
adjunct, as it is positive in SCC variants, but it is weakly
or not expressed in SNUC and SCNEC.17,18
SCC variants, particularly BSCC, and SCNEC must
also be differentiated from ACC with a predominantly
solid growth pattern, and from the so-called ‘dediffer-
entiated’ variant of ACC.43 ACC usually shows immu-
noreactivity for myoepithelial cell markers, including
common muscle actin, S100 protein, and calponin.
In addition, p63 is consistently expressed by both BSCC
and ACC, but whereas immunostaining is diffuse in
BSCC, ACC displays a consistently compartmentalized
pattern within tumour nests.44 Conversely, the dedif-
ferentiated component of dedifferentiated ACC is char-
acterized by loss of myoepithelial differentiation, and
lacks immunoreactivity for myoepithelial markers.43
Non-epithelial neoplasms
s inonasal malignant melanoma
Sinonasal melanoma represents between 0.5% and
1.5% of all melanomas and between 3% and 20% of
sinonasal malignant neoplasms.45–47 It most frequently
develops after the fifth decade of life, and it probably
originates from melanocytes present in the mucosa of
the respiratory tract.48 The majority of sinonasal
malignant melanomas are pigmented, and diagnosis
is usually straightforward. Those amelanotic lesions
consisting of sheets or nests of small round to oval cells
(Figure 5) may be difficult to distinguish from ON,
Ewing’s sarcoma ⁄ PNET, lymphomas, or undifferenti-
ated carcinomas. Those lesions with epithelioid
morphology should be differentiated from epithelioid
malignant schwannoma.49
Sinonasal melanoma shows positivity for S100 pro-
tein and consistent expression of other melanocytic
markers, including MART-1 ⁄melan-A, tyrosinase,
HMB-45, and Mitf.50 As a study of a large cohort of
patients has shown that no marker has a 100%
sensitivity, a panel of melanoma markers should be
employed to avoid misdiagnosis in occasional cases.51
In addition, the possibility of positive staining for other
Figure 4. Nuclear protein in testis (NUT) midline carcinoma of the
nasal cavity. The lesion is composed of nests of basaloid undifferen-
tiated cells, with focal areas of abrupt keratinization. Diffuse nuclear
immunoreactivity is observed with an anti-NUT monoclonal antibody
(lower right).
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markers such as synaptophysin, neurofilaments and
CD99 should be kept in mind.52–54 Ultrastructurally,
diagnostic melanin granules can be found in all cases.55
on
ON is an uncommon neoplasm that occurrs over a
broad age range, and characteristically originates in
the region of the cribriform plate from the olfactory
mucosa.56,57 A diagnosis of ‘ectopic’ ON, involving
other sites of the sinonasal region, requires a critical
differential diagnosis, mainly with SNUC, SCNEC, and
Ewing’s sarcoma ⁄ PNET. The correct identification of
ON is clinically relevant, in view of the fact that there
are excellent local and distant control rates with local
therapy alone, whereas SNUC, SCNEC and Ewing’s
sarcoma ⁄ PNET pursue a more aggressive clinical
course, requiring the use of combined-modality
therapy.6,58
More frequently, the tumour grows in nests sepa-
rated by fibrovascular septa, and the neoplastic cells
typically have a uniform appearance, with small and
round nuclei containing stippled chromatin, absent or
small nucleoli, and scanty cytoplasm. They are embed-
ded in a fibrillary background formed by cell processes.
Homer–Wright-type rosettes, or more rarely Flexner
rosettes, can be found.
Ancillary techniques are useful for the diagnosis,
especially in poorly differentiated lesions (Hyams grade
III and IV), in which neoplastic cells may be pleomor-
phic, mitotic figures may be numerous, there is necrosis,
and the neurofibrillary background is absent (Figure 6).
Immunohistochemically, ON shows diffuse positivity for
NSE and synaptophysin, whereas chromogranin, glial
fibrillary acidic protein (GFAP) and leu-7 are less often
positive.59 S100 protein stains sustentacular cells
around neoplastic nests, but, in less differentiated
tumours, there may be a few scattered S100 protein-
positive cells. Neurofilament protein and other markers
of neural differentiation are more often expressed in
tumours with a diffuse, sheet-like pattern. CKs are
generally negative, although, in ON with a nesting
pattern, a few tumour cells may exhibit staining for low
molecular weight CKs.60 EMA is consistently negative,
as are CD99, CD45, HMB-45 and muscle markers.
Ultrastructural analysis shows evidence of neuroblastic
differentiation, including the presence of dendritic
processes containing dense core granules and neurotu-
bules, and occasional synaptic junctions.55 ON lacks the
t(11; 22) translocation of Ewing’s sarcoma ⁄ PNET.61
In addition, ON also lacks the characteristic molecular
genetic changes of classic neuroblastoma, which may
be metastatic to the sinonasal region in children.
In children, ON must also be distinguished from RMS.
ewing’s sarcoma/pnet
Approximately 9% of cases of extraosseous Ewing’s
sarcoma ⁄ PNET arise in the head and neck region,
this being mostly a tumour of children and young
adults.62–65 The great majority of these tumours will
react strongly with antibodies against CD99 (MIC-2).66
This marker is of considerable value but it is by no
means specific, as a growing number of other neo-
plasms expressing this protein have been documented.
Among them are lymphomas, melanoma, mesenchy-
mal chondrosarcoma, SNUC, and SCNEC.24 Other
Figure 5. Malignant melanoma of the nasal cavity. A population of
undifferentiated round cells, with few pigmented elements, diffusely
infiltrates the mucosa. Neoplastic cells are positive for HMB45
(lower right).
Figure 6. High-grade olfactory neuroblastoma. The tumour is com-
posed of round cells, with mild pleomorphism, which show diffuse
staining for synaptophysin (lower right).
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antibodies that may offer diagnostic support are FLI1
and caveolin 1.67
Focal immunoreactivity for CKs can also sometimes
be detected. Other markers that may be expressed,
according to the degree of neuroectodermal differenti-
ation, are NSE, neurofilaments, synaptophysin, S100
protein, and GFAP. Ultrastructurally, Ewing’s sar-
coma ⁄ PNET may show rudimentary neural differenti-
ation, as well as scanty microtubule formation. The
main differential diagnosis is with ON, which is CD99-
negative, and with other small round cell tumours,
such as RMS and lymphoma. The detection of the
standard translocations of Ewing’s sarcoma ⁄ PNET is
useful to confirm the diagnosis and exclude ON.4,61
s inonasal haematolymphoid tumours
Lymphomas
Malignant lymphomas are the most frequent
non-epithelial malignancies of the sinonasal region,
representing between 6% and 14% of all sinonasal
malignancies.68,69 In western countries, approximately
50% are B-cell lymphomas, and, in this group, diffuse
large B-cell lymphoma is the most common.70–72 The
other 50% mostly show a natural killer (NK) ⁄ T-cell
lineage. Conversely, in oriental populations, the major-
ity of primary lymphomas of the nasal cavity and
nasopharynx are of the NK ⁄ T-cell lineage.73–75
Sinonasal B-cell lymphomas infiltrate and expand
the mucosa, and may extend into the underlying bone
(Figure 7). They lack epitheliotropism, polymorphous
cell infiltrate, angiocentricity, prominent necrosis, and
fibrosis. They are usually positive for B-cell markers
(CD20 and CD79a) and negative for NK ⁄ T-cell
markers. Kappa light chain restriction is seen more
often than restriction for lambda. EBV markers are
negative.
In sinonasal NK ⁄ T-cell lymphomas, an angiocentric
and angiodestructive infiltrate is frequently seen, com-
posed of small, medium-sized, large or anaplastic cells,
sometimes with a conspicuous admixture of inflam-
matory cells (Figure 8).76,77 Pseudoepitheliomatous
hyperplasia of the covering epithelium may occur, as
well as destruction of the mucosal glands. NK ⁄ T-cell
lymphoma is almost always associated with EBV
positivity (EBER-1). The most typical immunopheno-
type is CD2-positive, CD56-positive, surface CD3-
negative, and cytoplasmic CD3-positive.77 Most cases
are also positive for cytotoxic granule-associated
proteins (granzyme B, TIA-1, and perforin). Other
T ⁄ NK-cell-associated markers are usually negative.
Sinonasal lymphomas demonstrating CD3 positivity,
CD56 negativity, cytotoxic molecule positivity and EBV
positivity are also included within the NK ⁄ T-cell
category. It should be noted that other non-lymphoid
neoplasms of the sinonasal tract might be CD56-
positive, including ON, Ewing’s sarcoma ⁄ PNET, and
RMS.78 However, these entities can be distinguished on
the basis of positivity to other markers.
Extramedullary plasmacytoma
Plasmacytoma of the sinonasal tract appears as a
diffuse infiltration of neoplastic plasma cells of the
mucosa. Occasionally, tumour cells are less differenti-
ated, and the differential diagnosis with other sinonasal
Figure 7. Sinonasal large B-cell lymphoma. The mucosa is infiltrated
by a rather uniform population of large pleomorphic cells. The
tumour is diffusely positive for CD20 (upper right) and for bcl-6
(lower right).
Figure 8. Sinonasal natural killer (NK) ⁄ T-cell lymphoma. The infil-
trate is composed of lymphocytes of varying size. Some nuclei have an
irregular outline. Neoplastic cells are positive for CD56 (upper right)
and for Epstein–Barr virus (EBER-1, lower right).
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neoplasms may be difficult.79–82 Immunohistochemical
staining for CD38, CD138 and kappa and lambda
chains are helpful for the diagnosis.83
Granulocytic sarcoma
This is a localized tumour of malignant myeloid cells
that can rarely occur in the sinonasal tract.84,85 It may
develop prior to, concurrently with or following the
presentation of acute myeloid leukaemia. The mucosa
is infiltrated by diffuse sheets of primitive myeloid cells,
and the diagnosis can be confirmed with a panel
including chloroacetate esterase, myeloperoxidase,
lysozyme, and CD43, together with other B-cell and
T-cell lineage markers, in particular CD79a and
CD3.86,87 Leder staining for naphthol-AS-D chloroac-
etate esterase on paraffin sections can also be helpful.
Histiocytic sarcoma
Histiocytic sarcoma is a rare malignant neoplasm that
can occasionally involve the nasal cavity.88,89 Neo-
plastic cells are large and pleomorphic, with abundant
eosinophilic cytoplasm, well-defined cell borders, and
ovoid to irregular nuclei with large nucleoli. There is
usually an accompanying inflammatory infiltrate, most
often of neutrophils or lymphocytes. Neoplastic cells
are positive for LCA, CD45RO, CD4, CD68 (KP1 and
PG-M1), lysozyme, and CD31.89
sarcomas
Mesenchymal chondrosarcoma
Mesenchymal chondrosarcoma rarely originates in the
sinonasal tract.90 Microscopically, the lesion displays a
small, blue, round cell morphological appearance with
a haemangiopericytoma-like pattern. The diagnosis is
based on the recognition of foci of cartilaginous matrix
formation, which impart a biphasic appearance to the
tumour. The pattern of growth and absence of carti-
laginous matrix in biopsy material result in frequent
misdiagnosis. Tumour cells may be positive for CD99,
leading to confusion with other small-cell malig-
nancies, particularly with Ewing’s sarcoma ⁄ PNET.
Recently, it has been shown that immunohistochem-
ical positivity for the master regulator gene Sox-9 is
sensitive and specific for mesenchymal chondrosarco-
ma, and may be useful in the differential diagnosis with
other small round blue cell tumours.91,92
RMS
RMS is the most common sinonasal malignancy among
paediatric patients, but it is also observed in adults.93–95
The most common histological subtypes are the embry-
onal and the alveolar. A clear cell variant has also been
described.96 The diagnosis of poorly differentiated forms
requires immunohistochemical analysis for myogenin
and desmin.4 At the ultrastructural level, the diagnostic
features are rudimentary sarcomeres and other markers
of skeletal muscle differentiation, such as the ribosome–
filaments complexes. Alveolar RMS has a characteristic
translocation t(2;13)(q35;q14) fusing the PAX3 and
FKHR genes, which is particularly useful for distin-
guishing the solid variant from embryonal RMS.4
Poorly differentiated synovial sarcoma
Involvement of the sinonasal tract by synovial sarcoma
is exceedingly rare, but this tumour can be considered
in the differential diagnosis of undifferentiated primary
neoplasms of this region, because it may assume a
round cell Ewing-like morphology.97,98 Detection of
immunohistochemical positivity for CKs and EMA,
which is usually focal in poorly differentiated lesions,
and detection of the SS18 gene rearrangement are
necessary to confirm the diagnosis.98
Desmoplastic small round cell tumour
This is a tumour of uncertain histogenesis that most
commonly occurs in the abdominal cavity, but sporadic
cases have been reported in other locations, including
the sinonasal region.99 In this anatomical location, the
differential diagnosis includes SNUC, ON, lymphoma,
Ewing’s sarcoma, and embryonal and alveolar RMS.99
Desmoplastic small round cell tumour consistently
shows a t(11;22) (p13;q12) translocation, involving
the Wilms’ tumour suppressor gene (WT1) and the
Ewing’s sarcoma gene (EWS). The lesion is composed of
islands of round cells, separated by varying amounts
of desmoplastic stroma. The immunophenotype is
characteristic, with multidirectional differentiation
resulting in coexpression of epithelial (keratins and
EMA), mesenchymal (vimentin and desmin) and neural
(NSE and CD56) markers. With antibodies against the
C-terminus, nuclear positivity for WT1 can be detected
in tumour cells.
Summary and conclusions
The sinonasal region hosts a variety of tumours with a
‘undifferentiated’ light microscopic appearance, in
which careful morphological study and the use of
ancillary techniques is essential for an accurate diag-
nosis. Clinical data, including anatomical localization,
and age and sex of the patient, may also provide
relevant diagnostic information. For example, a diag-
nosis of ON is highly unlikely for a tumour occurring
outside the cribriform plate area, whereas the
differential diagnosis of a sinonasal undifferentiated
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malignancy in the paediatric age group mainly
includes RMS and Ewing’s sarcoma ⁄ PNET.
Immunohistochemistry has proven to be an extre-
mely powerful tool in the analysis of undifferentiated
sinonasal malignancies, and remains the main addi-
tional technique for the identification of specific tumour
categories and for the classification of these neoplasms.
Through careful microscopic examination of haemat-
oxylin and eosin-stained sections in the light of clinical
information, a list of differential diagnoses can be made
and an appropriate panel of antibodies can be chosen to
further categorize the tumour. An initial panel includ-
ing CKs, synaptophysin, S100 protein, desmin and
CD45 may allow the classification of most lesions or
may help to narrow the list of differential diagnoses
(Table 2). Further refinement can be obtained through
second-line markers, including in-situ hybridization
for EBV, other neuroendocrine markers, melanocytic
markers, myogenin, CD99, other lymphocyte markers,
and CD138 and light chains. The main limit of
immunohistochemistry remains the lack of specificity
of some markers.
The ultrastructural examination of neoplasms with
undifferentiated morphology on light microscopy is
always advisable and can furnish highly valuable data.
Electron microscopy can complement the light micro-
scopic diagnosis and the immunohistochemical find-
ings or, in a significant number of cases, can allow the
establishment of a definitive diagnosis identifying
subcellular organelles, structures and ⁄ or products that
are not otherwise recognizable. Distinctive filamentous
structures (keratin filaments, myofilaments, and micro-
tubules), deposits (glycogen), organelles (secretory or
neurosecretory granules, melanosomes, and well-devel-
oped endoplasmic reticulum) and membrane special-
izations (desmosomes, microvilli, and basal lamina) are
the features that help in the differential diagnosis at the
ultrastructural level.
Table 2. Summary of markers useful in the differential diagnosis of selected histological subtypes of undifferentiated sinonasal
neoplasm
CK SYN S100 CD45 Desmin EBV
Molecular
diagnostics
Sinonasal
undifferentiated
carcinoma
7+, 8+,
5 ⁄ 6), 13)
)
(focal +)
) ) ) ) )
Nasopharymgeal-type
undifferentiated
carcinoma
Pan+, 5 ⁄ 6+,
13+
) ) ) ) + )
Small-cell
neuroendocrine
carcinoma
Pan+, 5 ⁄ 6) + ) ) ) ) )
Basaloid squamous cell
carcinoma
Pan+, 5 ⁄ 6+ ) ) ) ) ) )
NUT midline carcinoma Pan+, 7+ ) ) ) ) ) t(15;19)
Olfactory
neuroblastoma
) (rarely focal +) + Sustentacular
cells
) ) ) )
Melanoma ) (rarely focal +) ) (rarely +) + ) ) ) )
Lymphoma ) ) ) + ) + in NK ⁄
T cell
)
Rhadomyosarcoma ) (rarely focal +) ) ) ) + ) t(2;13)
alveolar
Ewing’s sarcoma ) (rarely focal +) ) (focal +) ) (focal +) ) ) ) t(11;22)
CK, Cytokeratin; EBV, Epstein–Barr virus; NK, natural killer; NUT, nuclear protein in testis; Pan, pancytokeratin;
SYN, synaptophysin.
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Finally, molecular markers are becoming increas-
ingly important for the correct diagnosis of selected
undifferentiated sinonasal tumours, because they allow
the identification of entities for which other diagnostic
criteria may not be sufficiently specific, such as NMC,
Ewing’s sarcoma, alveolar RMS, poorly differentiated
synovial sarcoma, and desmoplastic small round cell
tumour.
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